Navitoclax (ABT-263)

For research use only.

Catalog No.S1001

182 publications

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Navitoclax (ABT-263) has been cited by 182 publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell M1;D[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXQZnBKSzVyPUCuNFA3PjlizszN MkfyV2FPT0WU
MV-4-11 NXjyTXBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PwU2lEPTB;MD6wNVU5PiEQvF2= M3LCcHNCVkeHUh?=
NKM-1 NUfWcWNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\ITWM2OD1yLkCxOlk6KM7:TR?= MWrTRW5ITVJ?
ML-2 MmXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwMEG5PFMh|ryP MmjBV2FPT0WU
BV-173 NIP6XoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHvPFgzUUN3ME2wMlAzOzF2IN88US=> MU\TRW5ITVJ?
RS4-11 M3H4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTCTWM2OD1yLkCyOVg4KM7:TR?= MmXzV2FPT0WU
HL-60 NEO1bWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwMEK5NFgh|ryP NEXnWJRUSU6JRWK=
KY821 M2rmdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfFTWM2OD1yLkCyPVc2KM7:TR?= MUPTRW5ITVJ?
ECC10 NVP6T4xsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFP3cFJKSzVyPUCuNFM4QTJizszN NWriTXlRW0GQR1XS
NCI-H720 M2nMeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TVWWlEPTB;MD6wOFAyOSEQvF2= NI\JemhUSU6JRWK=
QIMR-WIL NETWPIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HScmlEPTB;MD6wOFI5PyEQvF2= MoXXV2FPT0WU
KG-1 MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn64TWM2OD1yLkC0OFg3KM7:TR?= M37ISnNCVkeHUh?=
TGW MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPxTWM2OD1yLkC0OlM{KM7:TR?= MlTMV2FPT0WU
ATN-1 NHy3OZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMES3N|Mh|ryP Mo[wV2FPT0WU
RH-18 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzPTWM2OD1yLkC2NFQ5KM7:TR?= MojJV2FPT0WU
EW-18 NHnvW3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfHTWM2OD1yLkC2PFQyKM7:TR?= M4\0XnNCVkeHUh?=
NB17 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEG1R21KSzVyPUCuNFcyOjRizszN M3W0fHNCVkeHUh?=
SK-NEP-1 MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwMEeyNVMh|ryP M4DEcXNCVkeHUh?=
P12-ICHIKAWA MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPSc5g1UUN3ME2wMlA4Pzd6IN88US=> M2q0Z3NCVkeHUh?=
KARPAS-45 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwMEe4NVUh|ryP MUHTRW5ITVJ?
EW-3 M4LC[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4q5c2lEPTB;MD6wPFA2OyEQvF2= MUPTRW5ITVJ?
NB13 NXPrR4tWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPHTWM2OD1yLkC4NlA{KM7:TR?= MWjTRW5ITVJ?
NCI-H209 M4T3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTtT3ZJUUN3ME2wMlA5PzB2IN88US=> MljIV2FPT0WU
NCI-H1092 MkjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjzZVJ2UUN3ME2wMlExOjd3IN88US=> NH;v[mZUSU6JRWK=
NH-12 NILmV4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M374[GlEPTB;MD6xNFc1PCEQvF2= NFzlSFNUSU6JRWK=
697 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1P3PWlEPTB;MD6xNFg{QSEQvF2= MVXTRW5ITVJ?
KE-37 M1fJNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjNNJlKSzVyPUCuNVE{PyEQvF2= NXixd2Z{W0GQR1XS
MOLT-4 NYmyU2xET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXGyend2UUN3ME2wMlE2OTZ7IN88US=> MU\TRW5ITVJ?
CHP-134 NV24eHBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjYWnVJUUN3ME2wMlE3OzB4IN88US=> MoTOV2FPT0WU
D-283MED NYHOTHh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXpTWM2OD1yLkG3Olg3KM7:TR?= MX7TRW5ITVJ?
LU-135 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvYcndKSzVyPUCuNVg2PTJizszN MmnaV2FPT0WU
LU-134-A M{nje2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWm2[2dVUUN3ME2wMlE5PjdzIN88US=> NHzxRm9USU6JRWK=
EM-2 NYiydppNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPtNZFKSzVyPUCuNVk6OThizszN NUezeWVKW0GQR1XS
LU-139 M2rUbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwMkC0PVgh|ryP MmDvV2FPT0WU
ALL-PO NGfNNINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nOTmlEPTB;MD6yNVk5QCEQvF2= NFf1NVJUSU6JRWK=
NB12 NHv2[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzGOVI{UUN3ME2wMlI{OTF3IN88US=> MYrTRW5ITVJ?
KP-N-YN NV3FPFFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXWzcIZ{UUN3ME2wMlI{PTd|IN88US=> NHnmNZhUSU6JRWK=
BEN NUDwU3VUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMkO5Olgh|ryP MlTVV2FPT0WU
HCC1569 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGGwWo9KSzVyPUCuNlUyODZizszN M3zpXnNCVkeHUh?=
HuO9 M1vvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HYW2lEPTB;MD6yOlcyPSEQvF2= NEjGc4dUSU6JRWK=
WM-115 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rVVmlEPTB;MD6yO|c{QCEQvF2= MlHEV2FPT0WU
CCRF-CEM MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfYeo5KSzVyPUCuN|M2OjlizszN MnqzV2FPT0WU
IST-SL1 MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwM{WzOFMh|ryP MVLTRW5ITVJ?
BE-13 MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NESxNVBKSzVyPUCuN|Y1PTlizszN MmPrV2FPT0WU
COR-L88 NHzzbVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPYTWM2OD1yLkO2OVQh|ryP MkLrV2FPT0WU
DOHH-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTrSFBxUUN3ME2wMlQyODJ|IN88US=> NVTMNIpDW0GQR1XS
A704 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPVTWM2OD1yLkSyOlch|ryP NVixOI03W0GQR1XS
KNS-81-FD NUXmcYtyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DnUmlEPTB;MD60OFAyPyEQvF2= M1LodnNCVkeHUh?=
RPMI-8226 M{[xb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33UeGlEPTB;MD60OVY2OiEQvF2= NVi0d|E{W0GQR1XS
TGBC24TKB NW[zVndIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{D1[mlEPTB;MD60OVc4QCEQvF2= MlzYV2FPT0WU
NCI-H1304 M4XRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfxdYVKSzVyPUCuOFYyPTdizszN M2O4b3NCVkeHUh?=
MOLT-13 NHmwNWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3P[JRbUUN3ME2wMlQ3PjF|IN88US=> NFvTRVlUSU6JRWK=
EW-22 NWHmcpp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF31cYNKSzVyPUCuOFY3PzFizszN NH\qZ41USU6JRWK=
MS-1 MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrXTWM2OD1yLkS2PVM{KM7:TR?= NWjTfYlrW0GQR1XS
RMG-I M{PQVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwNEm0OlQh|ryP NHLlb3BUSU6JRWK=
NTERA-S-cl-D1 NWX2OHdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXIUW5ZUUN3ME2wMlUxODF7IN88US=> M1XGRXNCVkeHUh?=
NCI-H1048 M2TEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjiTWM2OD1yLkWwPVU{KM7:TR?= NH\UfJBUSU6JRWK=
SW1417 NGTDRppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfFTWM2OD1yLkW1OFM5KM7:TR?= M4i4VXNCVkeHUh?=
DB NHjm[m9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFP0emhKSzVyPUCuOVcxQCEQvF2= MmnZV2FPT0WU
MEG-01 NHzJZ2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TDOmlEPTB;MD61PFMzKM7:TR?= NFfJO|FUSU6JRWK=
EW-13 NV[2R4dYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[5UmlKSzVyPUCuOVg{PDFizszN NXTrV2JSW0GQR1XS
LAMA-84 M33JOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjCeGV5UUN3ME2wMlU6OjB5IN88US=> NVf2UnRpW0GQR1XS
J-RT3-T3-5 NXTYVldXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDvVYRKSzVyPUCuOlA5ODhizszN M3W1bXNCVkeHUh?=
MOLT-16 MnHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;3TWM2OD1yLk[1NlY1KM7:TR?= MmXIV2FPT0WU
DU-4475 MlrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\FW2lFUUN3ME2wMlY2PDJ5IN88US=> NIrIVJlUSU6JRWK=
HAL-01 MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwN{K1OFkh|ryP NEnoUZZUSU6JRWK=
RD M4\ufmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\xTWM2OD1yLke1PFk6KM7:TR?= MUDTRW5ITVJ?
OAW-28 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrkdGlKSzVyPUCuO|g{PyEQvF2= NHmzZ|dUSU6JRWK=
HCC38 NFrUXGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXYb5FKSzVyPUCuPFAyQSEQvF2= NEPFeIxUSU6JRWK=
NMC-G1 M2S4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwOEGxNlEh|ryP MW\TRW5ITVJ?
EW-16 NH;0T41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4CxemlEPTB;MD64NVMzQCEQvF2= MlvwV2FPT0WU
DU-145 MlP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwOEm5NlMh|ryP NHnoOHBUSU6JRWK=
HPAF-II MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwOUK2Nlgh|ryP MnzpV2FPT0WU
A427 Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\Je2pKSzVyPUCuPVMxOjJizszN NEH0[m9USU6JRWK=
PA-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPVdYczUUN3ME2wMlk2PjR{IN88US=> M1ewSnNCVkeHUh?=
OAW-42 M4PqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFO0fJpKSzVyPUCuPVYyPDZizszN M1i3TnNCVkeHUh?=
L-428 MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHIS3JKSzVyPUGuNFEzPSEQvF2= NWrmU3VKW0GQR1XS
COLO-824 NWnaVG0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTFwMEG3NFgh|ryP NVjSTINGW0GQR1XS
P30-OHK NVrabY56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXZTWM2OD1zLkC0Olg5KM7:TR?= M2nXcnNCVkeHUh?=
NCI-H2170 M1Ltd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ryNGlEPTB;MT6wOlI{KM7:TR?= NIjXUVJUSU6JRWK=
HCC2998 M3vtcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXsbYdKSzVyPUGuNFcyOzVizszN M1LJUXNCVkeHUh?=
NB14 NVXkU45qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUP1NYxSUUN3ME2xMlE{PzR6IN88US=> MXXTRW5ITVJ?
TGBC1TKB NFK3fJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTFwMUSxOVIh|ryP NVjaeZQ5W0GQR1XS
KP-N-YS NIjqeWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HtTmlEPTB;MT6xOlI{PiEQvF2= MVHTRW5ITVJ?
CAL-120 NVfBNI4xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLrTWM2OD1zLkG2OFI6KM7:TR?= MkTuV2FPT0WU
SBC-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXNPZlWUUN3ME2xMlE6ODV|IN88US=> Mn3TV2FPT0WU
C32 M3zG[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TtTWlEPTB;MT6xPVA5QCEQvF2= MVrTRW5ITVJ?
HCC2157 MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTFwMUm0PVQh|ryP NF72SYZUSU6JRWK=
COLO-792 NEn5Z4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof6TWM2OD1zLkKwNFcyKM7:TR?= NGTXN|RUSU6JRWK=
ES7 M1fWZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTFwMke5OVEh|ryP Mn;OV2FPT0WU
HEL MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXsZZFQUUN3ME2xMlMyODJ7IN88US=> NGO5fnFUSU6JRWK=
ES4 M362eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[yUGlEPTB;MT6zOFk6QCEQvF2= MXPTRW5ITVJ?
NCI-SNU-1 MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFwM{[1OVUh|ryP MnHiV2FPT0WU
MDA-MB-415 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rybWlEPTB;MT6zPFg2KM7:TR?= M{HwfXNCVkeHUh?=
NCI-H2342 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTFwNECyOlkh|ryP NV60dI5[W0GQR1XS
NB69 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTFwNE[yO|Eh|ryP NHnD[ppUSU6JRWK=
D-247MG MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nTcGlEPTB;MT61NVEzOiEQvF2= M4\zeHNCVkeHUh?=
SCC-4 MlrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoKyTWM2OD1zLkW5PFg4KM7:TR?= MoOzV2FPT0WU
HuH-7 NIm3UY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moq4TWM2OD1zLk[3Nlk{KM7:TR?= NF7FU2pUSU6JRWK=
A388 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTFwNki3NlQh|ryP NGfTVWpUSU6JRWK=
Calu-3 M4HOU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTWO5VKSzVyPUGuO|A3QTdizszN MonJV2FPT0WU
NCI-H1648 M3yxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\nUHlKSzVyPUGuO|E1OThizszN MWrTRW5ITVJ?
NCI-H2052 M1zZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jzW2lEPTB;MT63NlIxOSEQvF2= NYP1V3B[W0GQR1XS
Ramos-2G6-4C10 MkfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\OTWM2OD1zLkezOlU3KM7:TR?= MV;TRW5ITVJ?
DEL MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3nVGdKSzVyPUGuO|Q3QTJizszN NULUUpp5W0GQR1XS
SNU-423 MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37yUWlEPTB;MT63PFE2PyEQvF2= MUXTRW5ITVJ?
COR-L23 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz1V25KSzVyPUGuO|k5PzRizszN NGm2cphUSU6JRWK=
OMC-1 NYnSd4tjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXZTWM2OD1zLki2NFE3KM7:TR?= NEm3T4ZUSU6JRWK=
EW-11 NH3CS2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknFTWM2OD1zLkm1OlU4KM7:TR?= MXjTRW5ITVJ?
HSC-3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPWe446UUN3ME2xMlk3OzZ3IN88US=> NVrqdWVbW0GQR1XS
MLMA M1;TU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4n0cWlEPTB;MT65OlY4PyEQvF2= MkfwV2FPT0WU
RCM-1 NWe0XI5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fyVGlEPTB;Mj6wNFM6QSEQvF2= M2nSeHNCVkeHUh?=
MFE-280 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJwMEK4OFgh|ryP MoT3V2FPT0WU
ES8 NEPMUm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTlWnVVUUN3ME2yMlI2PDdzIN88US=> NU\oclAyW0GQR1XS
TE-11 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmmxTWM2OD1{LkK5OFc{KM7:TR?= MUTTRW5ITVJ?
HuO-3N1 NXXs[|JET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1n6dWlEPTB;Mj60PFc5KM7:TR?= MWPTRW5ITVJ?
MHH-NB-11 NFPMVGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTJwNUGxOVgh|ryP NIXpPFlUSU6JRWK=
TGBC11TKB M2rWbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rFVGlEPTB;Mj61O|Y5OSEQvF2= Ml;0V2FPT0WU
HOP-92 NWKyNZFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDPbFFUUUN3ME2yMlU5PzR|IN88US=> NWTSO2xiW0GQR1XS
IGR-1 MlPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHVbXNDUUN3ME2yMlYzODN3IN88US=> NYHnU|JCW0GQR1XS
GOTO NVjrNplkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7pPGdKSzVyPUKuOlU{PzdizszN M1TJ[XNCVkeHUh?=
NCI-H1650 M2SxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fsTWlEPTB;Mj63NlIyPSEQvF2= M360SXNCVkeHUh?=
NCI-H1581 NH[wXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTJwN{m2PFEh|ryP NIPISGZUSU6JRWK=
NCI-H2405 NXWwOGs3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXIcYZKSzVyPUKuPFI4QDJizszN MnS5V2FPT0WU
U-118-MG NGjSOmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV65OmNCUUN3ME2yMlk3PDlzIN88US=> MWPTRW5ITVJ?
DoTc2-4510 M4jiOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTNwMEG0NVch|ryP NV3se5R[W0GQR1XS
NCI-H596 MlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTNwMES5PVch|ryP MWTTRW5ITVJ?
MPP-89 MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnGwTWM2OD1|LkC1OlY3KM7:TR?= NF\mVXRUSU6JRWK=
GCIY Mor0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnDTXJVUUN3ME2zMlIxPDlzIN88US=> MYfTRW5ITVJ?
SW626 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXZTWM2OD1|LkK0OVQ{KM7:TR?= M371NnNCVkeHUh?=
OCI-AML2 M2DnTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TxcWlEPTB;Mz6zNVI4OiEQvF2= NGD4PYtUSU6JRWK=
NBsusSR MnSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7ueVFrUUN3ME2zMlM1QTN6IN88US=> MnLjV2FPT0WU
AN3-CA Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXJbI85UUN3ME2zMlQ1OjN6IN88US=> MoTLV2FPT0WU
EFM-19 M2Xqe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPz[lJKSzVyPUOuOFg{OzlizszN M{joSnNCVkeHUh?=
RVH-421 NGTjdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHBTWM2OD1|LkW2PFc4KM7:TR?= NVKwPXcxW0GQR1XS
5637 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDVTWM2OD1|Lk[xNVA{KM7:TR?= NWDPVZZCW0GQR1XS
PANC-08-13 MkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTaTWM2OD1|Lk[zOFczKM7:TR?= M2PNcnNCVkeHUh?=
H9 NX[1dVBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jaN2lEPTB;Mz62O|E1PCEQvF2= M1fWRXNCVkeHUh?=
KARPAS-299 NIPlc4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTNwNkezOlEh|ryP NXnueVBRW0GQR1XS
TE-5 NVLPeVhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrLTWM2OD1|LkewO|A6KM7:TR?= NWfBUnVqW0GQR1XS
NOS-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;3cIczUUN3ME2zMlc6QDN2IN88US=> MnjWV2FPT0WU
HH M4HH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTSNo1KSzVyPUOuPFM5PjhizszN M1PX[HNCVkeHUh?=
769-P NI\TeIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;mVHRHUUN3ME2zMlg6PTFizszN M2C4cXNCVkeHUh?=
CHP-212 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnFTWM2OD1|LkmyOVQ6KM7:TR?= MX\TRW5ITVJ?
NCI-H82 MonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHSe2R2UUN3ME2zMlk2QTN4IN88US=> NHn6WlBUSU6JRWK=
Mo-T MnP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTRwMESzNVIh|ryP MlewV2FPT0WU
BB65-RCC NEfs[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTRwMESzPVkh|ryP MYTTRW5ITVJ?
SW1990 M2jtbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvQV5R4UUN3ME20MlA2QTB6IN88US=> NIewSoxUSU6JRWK=
LK-2 M{LtZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTRwMUGyPVMh|ryP MXLTRW5ITVJ?
ES5 NVX3TVFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mon0TWM2OD12LkGzPVg2KM7:TR?= M4H5bnNCVkeHUh?=
JVM-3 NWO4bHU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f3[2lEPTB;ND6xPFIzOiEQvF2= NFjX[3BUSU6JRWK=
RPMI-7951 M3XPPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFi1bYJKSzVyPUSuNlI1OTNizszN M13Qd3NCVkeHUh?=
Calu-6 Mmm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYD2Vo5SUUN3ME20MlI4QDhzIN88US=> M1faPXNCVkeHUh?=
LC-2-ad M4f4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTRwMkm1Olgh|ryP M{n2dHNCVkeHUh?=
SW954 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnifIpKSzVyPUSuNlk3PiEQvF2= MnywV2FPT0WU
H-EMC-SS NU\sdHJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILkWXpKSzVyPUSuN|E5OzFizszN NEH6SXBUSU6JRWK=
ES3 NXqwdVhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7Y[Yd5UUN3ME20MlM2PDRzIN88US=> MoLlV2FPT0WU
no-11 NYDkUHpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTRwM{W1OVQh|ryP MXXTRW5ITVJ?
LAN-6 NWHqN5JTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzlZ25KSzVyPUSuOFUyQDlizszN NGDGUJpUSU6JRWK=
FTC-133 M4P3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHqzbGNKSzVyPUSuOVM6PSEQvF2= M2XjWHNCVkeHUh?=
8505C MkTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWD1XotQUUN3ME20MlU1OjNizszN NHLDb45USU6JRWK=
SW620 NWLYfWRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTRwNUewOVch|ryP MVPTRW5ITVJ?
BCPAP MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL6T5BrUUN3ME20MlY{PDhzIN88US=> M1fUZ3NCVkeHUh?=
SK-LU-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[1d3JGUUN3ME20MlY3ODh7IN88US=> NU\oPVBbW0GQR1XS
NCI-H1623 M3H5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonKTWM2OD12LkewNlI5KM7:TR?= MVLTRW5ITVJ?
C2BBe1 NXHOV|VpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXvTJpKSzVyPUSuO|QxODhizszN NEnVNJFUSU6JRWK=
GP5d M1fF[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTRwN{izPFgh|ryP NVLVeGQ2W0GQR1XS
NB6 Mn\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT5NpNbUUN3ME20Mlg3OjB2IN88US=> MUPTRW5ITVJ?
MDA-MB-157 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\VNIJKSzVyPUSuPFg4PiEQvF2= M2f4VXNCVkeHUh?=
UMC-11 NFjmWW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LkOGlEPTB;ND64PFk3PCEQvF2= MlzSV2FPT0WU
HCC1419 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LHTmlEPTB;ND65NFA3OyEQvF2= Mn;BV2FPT0WU
NCI-H2029 NITVVZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTRwOUSxPFUh|ryP MoHiV2FPT0WU
LXF-289 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HjeWlEPTB;NT6wN|cyQSEQvF2= M122[3NCVkeHUh?=
KINGS-1 NXPyV4ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7YcotKSzVyPUWuNFc4PDRizszN NHO4[lVUSU6JRWK=
HD-MY-Z NELGR4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\RTWM2OD13LkKzPVY6KM7:TR?= MX3TRW5ITVJ?
ESS-1 Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XofWlEPTB;NT6yOVU6PyEQvF2= MY\TRW5ITVJ?
GI-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHCT4VSUUN3ME21MlI4QTJ4IN88US=> NWG5TYQ2W0GQR1XS
RPMI-2650 M3TQWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1W5R2lEPTB;NT6zOlE3KM7:TR?= MoGwV2FPT0WU
IA-LM MmnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;3WGlEPTB;NT6zPVg4OSEQvF2= MYfTRW5ITVJ?
KP-4 NYnqOFRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLKdIVVUUN3ME21MlQ3OzN2IN88US=> NFP2PG5USU6JRWK=
G-402 M37F[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHJdWpqUUN3ME21MlUyQDZ3IN88US=> NILoZVRUSU6JRWK=
OS-RC-2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mke2TWM2OD13LkWyOlA1KM7:TR?= M1e4ZXNCVkeHUh?=
NCI-H1155 M4G2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\3cWlEPTB;NT61OFk2PSEQvF2= NHvhS4lUSU6JRWK=
OE19 NIrrfIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGn5[mtKSzVyPUWuOlg3OjRizszN NGjPS2VUSU6JRWK=
U-2-OS MojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHMbZI{UUN3ME21Mlg6ODF|IN88US=> MmDsV2FPT0WU
SCC-15 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\zTWM2OD13LkmzOlYzKM7:TR?= NXSxT4dJW0GQR1XS
NCI-H630 NVnXbXZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLWVXE3UUN3ME21Mlk6PDB2IN88US=> NFXJSmtUSU6JRWK=
PFSK-1 MknGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTZwMEWyOVkh|ryP M2CzV3NCVkeHUh?=
NCI-H1770 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\TPJZKSzVyPU[uNlA5PzRizszN M3nnVnNCVkeHUh?=
SK-MEL-3 NUi3d3NrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTZwNEK5NVUh|ryP M3W5enNCVkeHUh?=
LB1047-RCC MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF6z[pRKSzVyPU[uOFc3OjVizszN Mnf5V2FPT0WU
NCI-H446 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV23WoJ6UUN3ME22MlYzQTJ3IN88US=> M3f2S3NCVkeHUh?=
SW780 NGXXPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWX1UWFkUUN3ME22MlcxOTh3IN88US=> MnrIV2FPT0WU
NEC8 NWjsR4ptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDMcm5KSzVyPU[uO|Y3OyEQvF2= M{H1PXNCVkeHUh?=
NOMO-1 NFnaOoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHGe5lKSzVyPU[uO|gyOTFizszN MnzPV2FPT0WU
COLO-668 NU\oSndGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoGzTWM2OD14Lki0N|g4KM7:TR?= Mn\tV2FPT0WU
MC116 NEDQeVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTZwOUO4PVch|ryP NVXNemR[W0GQR1XS
HCC1937 Mkn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorFTWM2OD14Lkm5NlUyKM7:TR?= MVHTRW5ITVJ?
NCI-N87 Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD2dmlGUUN3ME23MlE6Ojl|IN88US=> MVLTRW5ITVJ?
COLO-320-HSR NX\hd3VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TZUmlEPTB;Nz6yNlc{QCEQvF2= MorpV2FPT0WU
HCC1806 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\vO2pUUUN3ME23MlI3ODR2IN88US=> NYPTUlF2W0GQR1XS
OVCAR-3 NH;zdYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7MeY9KSzVyPUeuN|MxOzhizszN MWnTRW5ITVJ?
NUGC-3 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXwd5hDUUN3ME23MlM6Pjl2IN88US=> NYHHd4ZMW0GQR1XS
SW1783 NV\ZSIY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF30eGdKSzVyPUeuOFMyPzVizszN MYjTRW5ITVJ?
GCT MnqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTdwNU[5NFYh|ryP MlH4V2FPT0WU
NCI-H2126 M4e2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGD4dpdKSzVyPUeuO|M3OjVizszN MY\TRW5ITVJ?
MEL-HO MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPRTWM2OD15Lke3NFU1KM7:TR?= NWrrUVdsW0GQR1XS
CAPAN-1 M4PwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTdwN{ezOVch|ryP NG\HeZNUSU6JRWK=
SW756 NFPjNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTzTWM2OD15Lke4N|M{KM7:TR?= NHy5T|NUSU6JRWK=
SKG-IIIa NIO5SHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnK3TWM2OD15LkixPFkzKM7:TR?= Mm\rV2FPT0WU
HCE-T NGO5cVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUmzc|FoUUN3ME23Mlg4Pzh|IN88US=> MWHTRW5ITVJ?
Ca-Ski NVTMT4hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDFdWNKSzVyPUeuPVk{QDNizszN Ml32V2FPT0WU
COLO-684 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRThwMEG4NVgh|ryP MXzTRW5ITVJ?
KYSE-70 NYXv[ph2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFeyUWxKSzVyPUiuNFc4OjlizszN M{m2WHNCVkeHUh?=
TI-73 NXflPIdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjGenF2UUN3ME24MlI2QDVzIN88US=> MlH0V2FPT0WU
BT-20 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLKbHNKSzVyPUiuNlYxPTJizszN MWPTRW5ITVJ?
MHH-ES-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjQc4pKSzVyPUiuOVE5OzRizszN MVjTRW5ITVJ?
TE-12 MojxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmq4TWM2OD16LkW5PVMyKM7:TR?= MUDTRW5ITVJ?
YH-13 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33JRmlEPTB;OD62NVAxQCEQvF2= M2DhbnNCVkeHUh?=
SF126 NEHEWlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHl[4FKSzVyPUiuPFM5PjVizszN NUPhS5h1W0GQR1XS
J82 M37yV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRThwOUCwN|gh|ryP M{fNdXNCVkeHUh?=
RCC10RGB MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnvTWM2OD16Lkm5OVYyKM7:TR?= NUjwT4FPW0GQR1XS
SK-UT-1 NHqxdmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTlwMES5OFUh|ryP NXK3VWJPW0GQR1XS
LB2241-RCC MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTlwMUmxN|ch|ryP M323fnNCVkeHUh?=
LB996-RCC NHXUUohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHkU2dCUUN3ME25MlE6QDlizszN NUjSNo1GW0GQR1XS
EPLC-272H NWn6eGtyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjLOmZKSzVyPUmuN|c3PTdizszN NX3tRYkxW0GQR1XS
CTV-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTlwNU[1N|Ih|ryP NX7vcJM1W0GQR1XS
HSC-2 M1n2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7JR|RoUUN3ME25MlU4PTVizszN MoXpV2FPT0WU
SK-MEL-28 MmTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjlSJJKSzVyPUmuOlE5QTNizszN NHr1S5hUSU6JRWK=
MMAC-SF MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTlwNki3OUDPxE1? MWrTRW5ITVJ?
CP50-MEL-B MoHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTlwN{W3PFIh|ryP MnzQV2FPT0WU
HT-1080 MoLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDhZm5KSzVyPUmuO|c4OzlizszN NW\kZY9SW0GQR1XS
HEC-1 Mo\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHhO2pKSzVyPUGwMlM{PTJizszN NI\6SItUSU6JRWK=
AGS NUnzd2tTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTFyLkO3OEDPxE1? NFrBVZdUSU6JRWK=
GAMG MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVj3WZBmUUN3ME2xNE42OTZ{IN88US=> M4O4NnNCVkeHUh?=
SW48 NHj3WmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;BemFKSzVyPUGwMlUyQDlizszN MXTTRW5ITVJ?
U031 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTFyLkW5NFgh|ryP MmrXV2FPT0WU
OVCAR-5 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2W2c2lEPTB;MUCuOlQzQSEQvF2= NVrxblBYW0GQR1XS
SF295 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjKfpN6UUN3ME2xNE43PzB2IN88US=> NGDtSIxUSU6JRWK=
BHT-101 NVziXmM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\wXnJKSzVyPUGwMlcyPzdizszN MVXTRW5ITVJ?
VMRC-RCZ MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTFzLkOyNFEh|ryP MWrTRW5ITVJ?
ACHN NXjlW|NLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTFzLkSyNVEh|ryP MmrrV2FPT0WU
NCI-H526 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnZZ3RKSzVyPUGxMlUxPDNizszN NU\yZ412W0GQR1XS
MN-60 NXz3dWV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2KyVGlEPTB;MUGuOVM6KM7:TR?= MVrTRW5ITVJ?
NCI-H2291 M37sSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWr0VJZvUUN3ME2xNU42PDZ4IN88US=> MYfTRW5ITVJ?
SCC-25 MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH6wUW9KSzVyPUGxMlc2PTZizszN Mm\4V2FPT0WU
SK-MEL-2 NGLF[HVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33YU2lEPTB;MUGuO|Y{PyEQvF2= MWHTRW5ITVJ?
SN12C NHLr[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTFzLkmzOVUh|ryP Mly2V2FPT0WU
NCI-H69 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTF{LkSyN|Qh|ryP M2HmSHNCVkeHUh?=
ME-180 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjS[YVpUUN3ME2xNk44ODV2IN88US=> MmrCV2FPT0WU
MC-IXC MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTF{Lke1NVgh|ryP NH20V4VUSU6JRWK=
NCI-H2347 M3W4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTPdGFSUUN3ME2xNk44PjF2IN88US=> MXnTRW5ITVJ?
M059J Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HnemlEPTB;MUKuO|czPyEQvF2= M1rFfXNCVkeHUh?=
A2058 NUPY[lE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4L6VmlEPTB;MUKuPFY5OSEQvF2= M3TlUHNCVkeHUh?=
VA-ES-BJ NUXVfoJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jnT2lEPTB;MUKuPFc5PSEQvF2= NXHTcIJpW0GQR1XS
Ca9-22 NHH4V2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3X4eGlEPTB;MUKuPVQ2OSEQvF2= M2C5c3NCVkeHUh?=
KNS-42 M1fHR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLsPHZKSzVyPUGyMlk6QDRizszN MY\TRW5ITVJ?
LoVo MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{W3c2lEPTB;MUOuNlMyOyEQvF2= NGK4O2VUSU6JRWK=
AM-38 NHHmeW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXhW4hKSzVyPUGzMlI2PjZizszN NFLUb4RUSU6JRWK=
NB5 M376Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYD2RlI6UUN3ME2xN{4{PzV{IN88US=> NFPNO4tUSU6JRWK=
L-363 NUPzfnZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrrbYtrUUN3ME2xN{41ODN|IN88US=> Mnr6V2FPT0WU
SK-MEL-30 NV\zc25FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTF2LkC2OFUh|ryP MojUV2FPT0WU
NCI-H1563 M1W5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTF2Lk[wN|kh|ryP NVrLWlBMW0GQR1XS
NCI-H2228 MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\qOWNKSzVyPUG0MlYxPzdizszN M{nt[HNCVkeHUh?=
MFM-223 MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV6wcJNzUUN3ME2xOU4yQDF|IN88US=> NHjEXYxUSU6JRWK=
LB831-BLC MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTF3LkK3Olch|ryP M4\KNnNCVkeHUh?=
SW872 NHf2fIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmH3TWM2OD1zNT6zNFg3KM7:TR?= NUHDVXYzW0GQR1XS
NCI-H522 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPLPGhKSzVyPUG1MlM{ODZizszN M3HYUHNCVkeHUh?=
EW-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHDZWRKSzVyPUG1MlU1PjJizszN NEG1eJZUSU6JRWK=
HN MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fRT2lEPTB;MUWuOVk1OiEQvF2= M4\VZXNCVkeHUh?=
SW837 M1LMW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\iflBLUUN3ME2xOU44QDR5IN88US=> MUDTRW5ITVJ?
SCC-9 MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTYWW9KSzVyPUG1MlgyOTRizszN NVfZ[GRUW0GQR1XS
MKN7 NITVdodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3jPY1KSzVyPUG1Mlk4OzJizszN NIDMNo9USU6JRWK=
KYSE-410 MnzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTF4LkW5NUDPxE1? NV;JcVVSW0GQR1XS
SK-N-DZ NX;0SYlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFK4dFNKSzVyPUG2MlYyOTZizszN MUjTRW5ITVJ?
COR-L105 MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXaXVFoUUN3ME2xOk43PTJ6IN88US=> NHj5Z5RUSU6JRWK=
LB2518-MEL M1PQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvUfm9KSzVyPUG2Mlg{QDlizszN M2rIfXNCVkeHUh?=
OVCAR-4 NVr3NoRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTF4Lki4OlIh|ryP NH3JWWhUSU6JRWK=
TK10 NV3KfoNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1iwSWlEPTB;MU[uPVQ4OyEQvF2= M{PKU3NCVkeHUh?=
KNS-62 MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTF4Lkm3O|ch|ryP M37LOnNCVkeHUh?=
RPMI-8866 M4DxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTF5LkG3N|Ih|ryP MXfTRW5ITVJ?
HuP-T4 NFGyWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTF5LkK0PVUh|ryP NFv5[|NUSU6JRWK=
CGTH-W-1 NYrTTlc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3FdGhuUUN3ME2xO{42OjF7IN88US=> NHTMTlNUSU6JRWK=
T-24 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{L0TGlEPTB;MUeuOVM1PyEQvF2= NYnidZR4W0GQR1XS
HT-3 M3TQT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTF5LkW5NVQh|ryP NVP2TY9yW0GQR1XS
KS-1 M{fKXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTF5Lk[3N{DPxE1? MXrTRW5ITVJ?
NCI-H1792 NVzr[I1xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPReoxnUUN3ME2xO{44QThizszN NETONpVUSU6JRWK=
ABC-1 Ml:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkG4TWM2OD1zNz64NVQyKM7:TR?= NYflPXA2W0GQR1XS
BPH-1 NXuySIxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTF6LkG2PFUh|ryP NXrQRmRxW0GQR1XS
A431 Mn7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnsdY1KSzVyPUG4MlQyOjdizszN NIHiXFdUSU6JRWK=
T98G NUfwSIxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;mbVdpUUN3ME2xPE42OTV5IN88US=> M3KyT3NCVkeHUh?=
BHY MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NET3VWFKSzVyPUG4Mlg3QSEQvF2= NF24[YFUSU6JRWK=
Capan-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTF6LkmwO|gh|ryP MnLQV2FPT0WU
MDA-MB-175-VII Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHX0Tm1KSzVyPUG4MlkzODlizszN M{nScnNCVkeHUh?=
CAL-27 NYfTPXNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M161SGlEPTB;MUmuNFQ5PyEQvF2= MYnTRW5ITVJ?
AsPC-1 MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTF7Lki2OVch|ryP MofrV2FPT0WU
KU812 NXL2fJJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF7Lkm1O|Mh|ryP MXrTRW5ITVJ?
NCI-H441 M1;RVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzsdnFKSzVyPUKwMlAxOSEQvF2= NEPEPIFUSU6JRWK=
Mewo NHP5c4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJyLkGyPFgh|ryP MlXmV2FPT0WU
SK-MEL-24 Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfJTWM2OD1{MD6xOFc4KM7:TR?= MmfmV2FPT0WU
NCI-H727 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TJeWlEPTB;MkCuNlcxPCEQvF2= NWDhdYJbW0GQR1XS
EKVX M4P3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\yeHRKSzVyPUKwMlYxPiEQvF2= NVrHeVNlW0GQR1XS
RT-112 NVryOIp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPUTWM2OD1{MD62NVIzKM7:TR?= NHfZOnRUSU6JRWK=
CAMA-1 NVL6VpoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfqR49KSzVyPUKwMlk5ODNizszN M322T3NCVkeHUh?=
SW900 NHfFcWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTlSZlKUUN3ME2yNU4xOTR7IN88US=> M3XWe3NCVkeHUh?=
NCI-H23 NFjhWGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTJzLkGyO|ch|ryP MXPTRW5ITVJ?
SK-PN-DW NYHVTppYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTJzLkG2OFkh|ryP NG\M[2lUSU6JRWK=
BB30-HNC M3nrZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{C0NGlEPTB;MkGuNlc1PSEQvF2= M2D0XnNCVkeHUh?=
VM-CUB-1 NEnTWY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\CeGlEPTB;MkGuN|U{PiEQvF2= MWXTRW5ITVJ?
IST-MEL1 M3\XVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPqfYF[UUN3ME2yNU4{Pjl{IN88US=> M1fnZXNCVkeHUh?=
CTB-1 MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1naTGlEPTB;MkGuOFc2PSEQvF2= NWLU[41VW0GQR1XS
LCLC-103H NX;QU3UxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLG[HMxUUN3ME2yNk4yPTh{IN88US=> M{\Be3NCVkeHUh?=
PANC-03-27 MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTJ{LkWxOlkh|ryP NUnaXWpXW0GQR1XS
HTC-C3 M4nCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2niXWlEPTB;MkKuOVU2PSEQvF2= NIjtSY5USU6JRWK=
TE-8 NIe5dYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXHTWM2OD1{Mz6yOVY2KM7:TR?= NWPr[mF3W0GQR1XS
NCI-H292 NFT4[HNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjsOJpNUUN3ME2yOU4{PTN4IN88US=> MlLXV2FPT0WU
COLO-680N NIra[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvRWmlKSzVyPUK1MlY{OjlizszN NYi2TmtMW0GQR1XS
KYSE-520 NXTwUpNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHPTWM2OD1{NT62OFQh|ryP MVXTRW5ITVJ?
NB10 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFroTnZKSzVyPUK2MlMyOTdizszN MX;TRW5ITVJ?
NCI-H661 NH6zNoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnyW2lKSzVyPUK2MlQ4OTNizszN MlfOV2FPT0WU
GMS-10 NXrIfWd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJ4Lki2N|gh|ryP MXXTRW5ITVJ?
NCI-H2122 MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{O5SWlEPTB;Mk[uPVk6QCEQvF2= NG\uNGFUSU6JRWK=
OVCAR-8 MlHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PxOWlEPTB;MkeuNFY{QCEQvF2= NXzNRXVxW0GQR1XS
DJM-1 NIDEdZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLN[2pKSzVyPUK3MlE1PTRizszN MXLTRW5ITVJ?
UACC-893 MlPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLifo9KSzVyPUK3Mlk5PzhizszN NFPxdIVUSU6JRWK=
C8166 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJ6Lk[5N|gh|ryP MVfTRW5ITVJ?
NCI-H1693 NVfUbHpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfwUXlKSzVyPUK4MlY6PzVizszN MX3TRW5ITVJ?
TYK-nu NGnTS5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkK5TWM2OD1|MD6wN|Q2KM7:TR?= NFzlXWxUSU6JRWK=
SW1710 M33pTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfPTYRnUUN3ME2zNE4yOjZizszN MXrTRW5ITVJ?
A375 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;uTWM2OD1|MD6zNlQ{KM7:TR?= NVzrcJhxW0GQR1XS
HMV-II NFi0N3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTNzLkO1PVIh|ryP M{j1WnNCVkeHUh?=
NCI-H2087 NFG5fJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fMcmlEPTB;M{GuOlM2OiEQvF2= NX\lTmJ4W0GQR1XS
CAL-54 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTNzLkeyOFEh|ryP M2fZSXNCVkeHUh?=
HCC70 NVi3SlE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTYNWF2UUN3ME2zNk4yOzh5IN88US=> MkPBV2FPT0WU
ES1 NHTFWGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2K0UGlEPTB;M{KuN|A3OiEQvF2= M3naUXNCVkeHUh?=
NCI-H1355 M33memdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPETWM2OD1|Mz6yNFQh|ryP NW\TcYI4W0GQR1XS
CFPAC-1 NXLVeWN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\WOGlEPTB;M{OuNlM{OiEQvF2= NWDYXIlQW0GQR1XS
MKN28 M4PJeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3tTWM2OD1|Mz6zPFA6KM7:TR?= MkDyV2FPT0WU
HDLM-2 M2Hw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTN|Lk[5N|Eh|ryP MoTvV2FPT0WU
PANC-10-05 M4jkNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XUVGlEPTB;M{SuNVAyPCEQvF2= NWLqOHBLW0GQR1XS
SAS M3Lremdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUCxOlJLUUN3ME2zOE41PTZ3IN88US=> NX\iTWpxW0GQR1XS
HCC1395 MlzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTN2LkexPFYh|ryP NITL[XpUSU6JRWK=
8305C MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrLOmFKSzVyPUO1Mlg1OTVizszN NVrpd4N{W0GQR1XS
KM12 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjoRoY1UUN3ME2zOk44PTR5IN88US=> NGXJUYVUSU6JRWK=
SW1116 NYfjW2tOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGntVGVKSzVyPUO3MlU6QTJizszN MV;TRW5ITVJ?
SK-MEL-1 MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PqZWlEPTB;M{iuN|M5QSEQvF2= MXLTRW5ITVJ?
HCC2218 M3;iPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NES0O4xKSzVyPUO4MlY2OTlizszN NV\WfnBoW0GQR1XS
T84 NE\ielBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDOT496UUN3ME2zPE44PDB7IN88US=> NHzXbIhUSU6JRWK=
ETK-1 NGKwOGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{K4R2lEPTB;M{muNFIzKM7:TR?= M2eze3NCVkeHUh?=
COLO-800 Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmq1TWM2OD1|OT6zPFY5KM7:TR?= MWPTRW5ITVJ?
CAL-12T MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmW3TWM2OD1|OT61NlgyKM7:TR?= NInaVXdUSU6JRWK=
ACN NEXyU29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInsNWNKSzVyPUSwMlQ6OTFizszN NUjDbnFlW0GQR1XS
SJSA-1 NX7UNZVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn65TWM2OD12MT6xOVk3KM7:TR?= MnjpV2FPT0WU
PSN1 NEjBNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHtcohKSzVyPUSxMlE4PDlizszN M{nh[nNCVkeHUh?=
D-566MG NF3uOJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fRRmlEPTB;NEGuNlA5PiEQvF2= NXLKS5RZW0GQR1XS
EGI-1 NFLjO|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTteFRKSzVyPUSyMlQzQCEQvF2= MUHTRW5ITVJ?
A204 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHiyZmdKSzVyPUSyMlY{QDhizszN M4HxfXNCVkeHUh?=
Saos-2 M4Luemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\CNI1KSzVyPUSyMlg{PjlizszN NWDqeoJTW0GQR1XS
SNU-C2B MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2H1PGlEPTB;NEOuOlg4QCEQvF2= MWLTRW5ITVJ?
HLE NEfSXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTVTWM2OD12ND6wPFU3KM7:TR?= NEnk[4RUSU6JRWK=
SW1463 NUjndZBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGraOZRKSzVyPUS0Mlk6PzFizszN MWHTRW5ITVJ?
DSH1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrROJlYUUN3ME20OU4xODN|IN88US=> MX3TRW5ITVJ?
MCF7 MkjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjscZNKSzVyPUS1MlUxPTFizszN M3HCfnNCVkeHUh?=
K5 NXv6emtyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTR3Lkm0NFUh|ryP NV7GNm8yW0GQR1XS
NCI-H358 M4fRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml2xTWM2OD12Nz6yNVUh|ryP NXv0R3pZW0GQR1XS
NCI-H2030 Ml;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrOcG9KSzVyPUS3MlI{PzRizszN MXPTRW5ITVJ?
SW948 M2HGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfKS4NKSzVyPUS3MlQ3PCEQvF2= MmTOV2FPT0WU
BALL-1 M2HqUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTwRXA1UUN3ME20O{43OTZ6IN88US=> MoPRV2FPT0WU
TE-9 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n5VWlEPTB;NEeuPVU5OSEQvF2= NFLHRoFUSU6JRWK=
SK-N-FI MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnRNldKSzVyPUS4MlA{PThizszN MnK3V2FPT0WU
KALS-1 M4XNdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHaU29FUUN3ME20PE4yOjh7IN88US=> MW\TRW5ITVJ?
HO-1-N-1 NITkdHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTR6Lke0OFUh|ryP M2\RXnNCVkeHUh?=
NCI-H2452 NUfIe4NkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTR7LkGxOVIh|ryP MYPTRW5ITVJ?
OC-314 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTR7Lk[4N|Qh|ryP NYK2[pBQW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
STAT3 / pSTAT3 / STAT6 / pSTAT6 / Mcl-1 / Cleaved Mcl-1 / Bcl-xl / Bim / puma / Bik / Bax / PARP / c-Myc; 

PubMed: 26811457     


(A) Western blot analysis of expressions of STAT3/p-STAT3 and STAT6/p-STAT6 as well as antiapoptotic members (Bcl-2, Bcl-xL, and Mcl-1) after 48 h of treatments in HDLM-2 cells. (B) Western blot analysis of expressions of proapoptotic proteins (Bim, Puma, Bik, Bax, and p-Bad) as well as caspase cascade molecules (PARP and c-Myc) after 48 h of treatments. β-Actin was used as an input control.

caspase3 / cleaved caspase 3; 

PubMed: 24481442     


(b) (i) N/TERT, (ii) SINCE and (iii) SINEG2 cells were either untreated (0 μM/DMSO) or treated with increasing doses of Navitoclax (ABT-263; 0.025–30 μM) and were incubated for 24 h. Next, cells were collected and whole-cell lysates were prepared and immunoblotted against anti-full-length Caspase 3 (∼35 kDa) antibody, whereas β-actin (∼42 kDa) was used as a protein-loading control. Apoptosis was assessed through detecting the cleaved bands of Caspase-3 (∼19, 17 kDa). 

26811457 24481442
Growth inhibition assay
Cell viability; 

PubMed: 25685063     


(C) Hcc827, (D) H292, and (E) H1993 cells were treated with increasing concentrations of albendazole or mebendazole in the presence of navitoclax (0, 1, 2, and 4 μM). Viability was determined after 1 day.

25685063
In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

- Collapse

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

- Collapse
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.
7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
in solvent
Synonyms N/A

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03181126 Active not recruiting Drug: Navitoclax|Drug: Chemotherapy|Drug: Venetoclax Acute Lymphoblastic Leukemia (ALL)|Lymphoblastic Lymphoma AbbVie November 27 2017 Phase 1
NCT02520778 Active not recruiting Drug: Navitoclax|Drug: Osimertinib Advanced Lung Non-Squamous Non-Small Cell Carcinoma|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma|Stage III Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Lung Non-Small Cell Cancer AJCC v7 National Cancer Institute (NCI) March 31 2016 Phase 1
NCT02591095 Completed Drug: ABT-263 Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02079740 Recruiting Biological: Navitoclax|Drug: Trametinib Advanced Lung Carcinoma|Advanced Malignant Solid Neoplasm|Advanced Pancreatic Carcinoma|Malignant Female Reproductive System Neoplasm|Metastatic Malignant Solid Neoplasm|Recurrent Lung Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Pancreatic Carcinoma|Stage III Lung Cancer AJCC v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Lung Cancer AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Unresectable Malignant Solid Neoplasm National Cancer Institute (NCI) March 7 2014 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • Answer:

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • Question 2:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • Answer:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy Navitoclax|Navitoclax ic50|Navitoclax price|Navitoclax cost|Navitoclax solubility dmso|Navitoclax purchase|Navitoclax manufacturer|Navitoclax research buy|Navitoclax order|Navitoclax mouse|Navitoclax chemical structure|Navitoclax mw|Navitoclax molecular weight|Navitoclax datasheet|Navitoclax supplier|Navitoclax in vitro|Navitoclax cell line|Navitoclax concentration|Navitoclax nmr|Navitoclax in vivo|Navitoclax clinical trial|Navitoclax inhibitor|Navitoclax Apoptosis inhibitor|Navitoclax does
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID